伪酶PEAK1对CAMK2的激活代表了三阴性乳腺癌中可向的途径
Xue Yang1,2, Xiuquan Ma1,2, Tianyue Zhao1,2
1Cancer Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.
通过激活CAMK2,PEAK1伪基因酶驱动三阴性乳腺癌 (TNBC). 抑制这种PEAK1/CAMK2与RA306的相互作用减少了TNBC生长和转移,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 在预后不佳的癌症,如三阴性乳腺癌 (TNBC) 中,PEAK1-3伪基因酶是致癌的.
- 由于它们缺乏催化活性,因此很难准伪基因酶.
- 识别下游效应因子对于治疗开发至关重要.
研究的目的:
- 在TNBC中识别PEAK1效应器.
- 为了阐明PEAK1信号通路.
- 评估RA306作为针对PEAK1/CAMK2轴的治疗剂.
主要方法:
- 对PEAK1相互作用蛋白进行查.
- 研究信号通道 (PLCγ1/Ca2+).
- 使用第二代CAMK2抑制剂 (RA306) 在体外和体内TNBC模型.
主要成果:
- 已确定CAMK2D和CAMK2G是PEAK1效应体.
- 通过PLCγ1/Ca2+信号和直接结合,PEAK1激活CAMK2.
- 在CAMK2中酸化PEAK1,增强PEAK1/PEAK2关联和瘤信号.
- RA306抑制TNBC细胞迁移/入侵,并减弱异种移植生长/转移.
- PEAK1 消光镜 RA306 的效果.
结论:
- PEAK1作为一个信号连接点,集成和氨酸激酶通路.
- 在TNBC中,CAMK2是关键的下游效应因子和治疗性可操作的目标.
- 使用RA306对CAMK2的药理抑制显示出对TNBC的治疗潜力.
更多相关视频
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
cAMP-dependent Protein Kinase Pathways
